| Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients M Pestrin, S Bessi, F Galardi, M Truglia, A Biggeri, C Biagioni, ... Breast cancer research and treatment 118, 523-530, 2009 | 261 | 2009 |
| Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice A McCartney, I Migliaccio, M Bonechi, C Biagioni, D Romagnoli, ... Frontiers in oncology 9, 666, 2019 | 138 | 2019 |
| A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients … L Malorni, S Piazza, Y Ciani, C Guarducci, M Bonechi, C Biagioni, ... Oncotarget 7 (42), 68012, 2016 | 126 | 2016 |
| Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast … L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D’hollander, ... Annals of Oncology 29 (8), 1748-1754, 2018 | 92 | 2018 |
| Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer C Guarducci, M Bonechi, M Benelli, C Biagioni, G Boccalini, D Romagnoli, ... NPJ breast cancer 4 (1), 38, 2018 | 85 | 2018 |
| Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase S Catarzi, C Biagioni, E Giannoni, F Favilli, T Marcucci, T Iantomasi, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1745 (2), 166-175, 2005 | 79 | 2005 |
| Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial A McCartney, M Bonechi, F De Luca, C Biagioni, G Curigliano, E Moretti, ... Clinical cancer research 26 (9), 2131-2139, 2020 | 43 | 2020 |
| Cell-free DNA-methylation-based methods and applications in oncology F Galardi, F De Luca, D Romagnoli, C Biagioni, E Moretti, L Biganzoli, ... Biomolecules 10 (12), 1677, 2020 | 41 | 2020 |
| Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening … L Biganzoli, L Boni, D Becheri, E Zafarana, C Biagioni, S Cappadona, ... Annals of oncology 24 (2), 494-500, 2013 | 41 | 2013 |
| Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy M Bonechi, F Galardi, C Biagioni, F De Luca, M Bergqvist, M Neumüller, ... Oncotarget 9 (23), 16389, 2018 | 37 | 2018 |
| Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of … A McCartney, C Biagioni, G Schiavon, M Bergqvist, K Mattsson, ... European Journal of Cancer 114, 55-66, 2019 | 35 | 2019 |
| Redox State and O2•- Production in Neutrophils of Crohn's Disease Patients C Biagioni, F Favilli, S Catarzi, T Marcucci, M Fazi, F Tonelli, ... Experimental Biology and Medicine 231 (2), 186-195, 2006 | 33 | 2006 |
| Screening for frailty in older patients with early-stage solid tumors: a prospective longitudinal evaluation of three different geriatric tools L Biganzoli, AR Mislang, S Di Donato, D Becheri, C Biagioni, S Vitale, ... Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences …, 2017 | 31 | 2017 |
| ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data D Romagnoli, G Boccalini, M Bonechi, C Biagioni, P Fassan, R Bertorelli, ... BMC genomics 19, 1-7, 2018 | 27 | 2018 |
| Adjuvant systemic treatment for individual patients with triple negative breast cancer C Oakman, E Moretti, F Galardi, C Biagioni, L Santarpia, L Biganzoli, ... The Breast 20, S135-S141, 2011 | 25 | 2011 |
| TransCONFIRM: identification of a genetic signature of response to fulvestrant in advanced hormone receptor–positive breast cancer R Jeselsohn, WT Barry, I Migliaccio, C Biagioni, J Zhao, ... Clinical Cancer Research 22 (23), 5755-5764, 2016 | 23 | 2016 |
| A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients E Risi, A Grilli, I Migliaccio, C Biagioni, A McCartney, C Guarducci, ... Breast cancer research and treatment 170, 329-341, 2018 | 21 | 2018 |
| Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial F Galardi, F De Luca, C Biagioni, I Migliaccio, G Curigliano, AM Minisini, ... Breast Cancer Research 23, 1-12, 2021 | 19 | 2021 |
| Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled … L Rossi, C Biagioni, A McCartney, I Migliaccio, G Curigliano, G Sanna, ... Breast Cancer Research 21, 1-7, 2019 | 18 | 2019 |
| A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in … L Malorni, G Curigliano, AM Minisini, S Cinieri, C Tondini, G Arpino, ... Journal of Clinical Oncology 35 (15_suppl), 1002-1002, 2017 | 15 | 2017 |
Angelo Di LeoHospital of PratoZweryfikowany adres z uslcentro.toscana.it
